At a glance
ClinicalIndex Comparison RecordPhase 2Active· 53 enrolled
Drug / intervention
Chimeric Antigen Receptor T-Cell Therapy +4 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
In Brief
A Phase 2 clinical trial evaluating Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, and 3 other interventions for Recurrent B-Cell Non-Hodgkin Lymphoma and 22 related conditions. Active but no longer recruiting, targeting 53 participants across 1 site.
Detailed Summary
The purpose of this research is to find the best dose of genetically modified T-cells, to study the safety of this treatment, and to see how well it works in treating patients with B cell non-Hodgkin lymphoma that has come back (relapsed) or did not respond to previous treatment (refractory).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Marginal Zone Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Recurrent Central Nervous System Lymphoma, Refractory Central Nervous System Lymphoma
CountriesUnited States
CollaboratorsMustang Bio
Timeline
Phase 2Active
2018201920202021202220232024202520262027202820292030203120322033203420352036203720382039
First PostedSep 2017
Enrollment StartDec 2017
Primary CompletionMar 2024
TodayJul 2026
Study CompletionMar 2039
First PostedSep 11, 2017
Enrollment StartDec 5, 2017
Primary CompletionMar 29, 2024
Study CompletionMar 1, 2039
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 8.8 years ago
Interventions
Chimeric Antigen Receptor T-Cell Therapybiological
Given CD20 CAR T cell IV
Cyclophosphamidedrug
Given IV
Laboratory Biomarker Analysisother
Correlative studies
Leukapheresisprocedure
Undergo leukapheresis
Fludarabine Phosphatedrug
Given IV